At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular restenosis
Most Recent Events
- 28 Jul 1998 No-Development-Reported for Vascular restenosis in USA (Unknown route)
- 18 Dec 1995 Preclinical development for Vascular restenosis in USA (Unknown route)
- 10 Nov 1994 New profile